Keylika GTM brain

category

market profile

• text: Oral iron intolerance and intravenous infusion burden create demand for alternative delivery, although product claims need clinical validation.
• text: Riron is described as a dietary supplement with an estimated US launch in Q4 2026, distinct from the proposed prescription product.

personas

• title: Iron-deficient patient intolerant of oral supplements
  pains:

  • Nausea or constipation can make oral iron difficult to continue.
  • Infusions require a clinical visit and may be costly.
• title: Obstetrician-gynecologist or hematologist
  pains:

  • Patients may stop oral therapy because of gastrointestinal side effects.
  • Needs clinical evidence and clear regulatory status before recommending a new delivery format.

icp

• text: US adults experiencing iron deficiency who have difficulty tolerating or absorbing conventional oral iron; children and pregnancy require separate clinical guidance.
• text: Women's health and hematology practices managing iron-deficient patients are potential education and referral partners.

message pillars

• text: Combine formulation and delivery technology.
• text: Pursue a self-administered iron delivery option.
• text: Address iron deficiency as an underserved problem.

objections

• objection: Is the product approved and proven to treat anemia?
  response: Distinguish the proposed prescription drug from the dietary supplement and provide current regulatory status and human evidence; do not present development claims as established outcomes.
• objection: Will a patch absorb enough iron without GI symptoms?
  response: Share formulation-specific clinical absorption, tolerability and dosing evidence when available, and encourage consultation with a clinician.

competitors

• name: Shield Therapeutics
  why: Markets an oral prescription iron therapy for iron deficiency, an alternative treatment pathway.
• name: Rockwell Medical
  why: Provides iron therapies in anemia management, including for patients with kidney disease.

influencers

• name: Christy Evans
  url: https://www.linkedin.com/posts/christy-evans-md-facog-911b923_riron-is-poised-to-be-a-game-changer-in-the-activity-7442251579577184256-ckwL
  why: Ob-gyn and public advocate discussing Riron.

keywords

• iron deficiency supplement without stomach upset
• iron deficiency anemia treatment
• iron patch
• buccal iron supplement
• alternative to iron infusion
• oral iron intolerance

voice

• science-led
• patient-focused
• ambitious

signals

• text: Patient reports stopping oral iron due to gastrointestinal intolerance or difficulty absorbing it.
• text: Women's health practice is seeking options for recurring iron deficiency and tracks emerging delivery methods.

pricing

motion

channels

• LinkedIn
• healthcare press
• product website

confidence

Founders

• name: Buddha Chaudhuri
  title: Founder
  role: Founder
  bio: Buddha spearheaded the technology development of a microneedle-based biosensor from lab-to-fab for a Series B stage medtech startup. Having worked across 3 continents and 6 countries, he has been instrumental in developing novel healthcare technologies in leading global research institutes and biotech companies, for the last 15 years. Buddha earned his PhD from Imec / KU Leuven in Belgium, in Drug Delivery Microsystems. He also pursued a Postdoc at UC San Francisco (UCSF) / UC Berkeley.
• name: Frederik Ceyssens
  title: Founder
  role: Founder
  bio: With a deep passion for diverse technologies, I'm a true multi-domain expert. My interest go from tiny moving machines to nuclear space rockets, from electrical circuits to medical devices and beyond. Next to Keylika, I founded ReVision, a neurotech company aiming at restoring sight in blind people, developing widely useful high-res neurotech in the process. I have an EE PhD, a MSc. in IC design as well as a BSc. in Medicine.